FDA grants fast track designation for Lundbeck’s Lu AH69593

RegulatoryLu AH69593Positive

AI Analysis

Summary

Lundbeck has received FDA fast track designation for Lu AH69593, an investigational narcolepsy treatment. Fast track status accelerates the development and review process for the drug candidate.

Outcome Details

Fast track designation granted

Importance:6/10

Sentiment:

0.60

FDAfast track designationnarcolepsyinvestigational drug

Related Companies

$HLUYY

Read the original article

Published by Pharmaceutical Technology on July 24, 2026 8:40 AM

Read Original